1.Effect of irbesartan on nephrin expression in the podocyte of early diabetic nephropathy rats
Haibo LONG ; Juan ZHONG ; Lianbo WEI ; Weidong ZHOU ; Zhaozhong XU
Chinese Journal of Pathophysiology 1989;0(06):-
AIM: To investigate the expression of the nephrin in podocyte of the diabetic nephropathy(DN) rats and the mechanism of irbesartan-induced renal protection.METHODS: The DN model was established by a single injection of streptozotocin(STZ),and DN rats were randomly divided into 2 groups: model group and irbesartan treatment group.In addition,the normal rats served as a normal control group. All the rats were received daily gavage respectively for 8 weeks. The urinary protein quality in 24 hours,body weight(BW),kidney weight (KW),KW/BW,glucemia,urea nitrogen,creatinine,total cholesterol, triacylglycerol were detected with correlative methods and the pathological changes of kidney were also detected with optic microscope and transmission electron microscope.The expression of nephrin in podocyte were detected by immunohistochemistry. RESULTS: In DN rats, irbesartan reduced the urinary protein quality in 24 hours (P
2.Establishment of a fuzzy mathematical model for syndrome differentiation of gastric cancer.
Long LIU ; Ling XU ; Dazhi SUN ; Pinkang WEI
Journal of Integrative Medicine 2008;6(11):1117-21
To probe into a method for establishing the fuzzy mathematical model for syndrome differentiation of gastric cancer.
3.Report of state monitory network in the Kaschin-Beck Disease area , Gansu province in 2000
Ji-min, XU ; Wen-long, WANG ; Zhou-bang, WEI
Chinese Journal of Endemiology 2001;20(2):132-133
Objective According to Kaschin-Beck Disea se monitory standardization that had been adjusted by our country,we monitored the state of Kaschin-Beck Disease in Gansu province.Methods So as to understand change of illness,we took methods of epidemiological investigation,clinical examination and X-ray diagnosis.Results It is not detected in the clinical that patient suffered from more than I of KBD among 7~12 years old in Qingyang monitory netw ork.X-ray detectable rate is 3%,but 12 cases patients were showed in Zhangjiach uan.X-ray detectable rate is 22.22%.Conclusions Illness was showed steady state and was con trolled in Qingyang region,but illness recurred clearly in Zhangjiachuan region.
4.Not Available.
Long long CHENG ; Rong hui XU ; Wei YOU ; Hai xia WANG
Journal of Forensic Medicine 2021;37(5):749-751
5.Expression and Purification of a Novel Influenza Virus Subunit Vaccine
Yi-Ju WEI ; Hai-Ting LONG ; Xu YANG ; Jian-Fang LI ; Yan-Wei BI ; Jian-Feng LI ; Wei-Ming XU ;
China Biotechnology 2006;0(05):-
The influenza A virus matrix protein2 gene(M2)which deleted transmembrane region was amplified by overlap extending PCR,and the multiepitope gene of hemagglutinin(HA)was PCR amplified with seven continuous synthesized segments by designing primer.The two gene segments were separately cloned into pMD18T vector to sequence analysis and prokarytic expression vector pET28a+ to construct the recombinant plasmid pET28a+M2dHA.The recombinant plasmid was transformed into E.coli BL21(DE3),and the high expression strain was obtained by screening monoclones.The recombinant protein existed as inclusion bodies,which accounted about 45% of the total cellular protein.The inclusion bodies were washed with 1% Triton X100 solution twice,and dissolved in 8 mol/L urea solution.The solution protein was purified by Ni+2 affinity chromatography,and refolded by dilution renaturation,then purified by Q Sepharose FF cation exchange column.The purity of the protein was over 90% by HPLC analysis.The result of Western blot showed it has good antigenicity and specificity.These results strongly supported for the further study of the broadspectrum influenza virus subunit vaccine.
6.Master documentation and records in the clinical data management.
Hua-long SUN ; Gang XU ; Wei LI ; Zhao-hui WEI ; Li DING
Acta Pharmaceutica Sinica 2015;50(11):1365-1366
This list of clincal data management documentation is to ensure standardized and adequate archival of trial documents and records in clinical data management, which is applicable to all of phase I-IV clinical trials.
Clinical Trials as Topic
;
Data Collection
;
standards
;
Documentation
;
standards
7.Dose-effect relationship of nalbuphine preventing injection pain of medium plus long chain triglyceride propofol in pediatric patients undergoing gastroenteroscopy
Huanhuan ZHANG ; Yonghong TAN ; Xingrong SONG ; Yingyi XU ; Wei WEI ; Xiaofen LONG
Chinese Journal of Anesthesiology 2021;41(2):195-197
Objective:To determine the dose-effect relationship of nalbuphine preventing injection pain of medium plus long chain triglyceride propofol in pediatric patients undergoing gastroenteroscopy.Methods:Pediatric patients, aged 3-8 yr, of American Society of Anesthesiologists physical statusⅠ or Ⅱ, scheduled for elective gastroenteroscopy, were enrolled in the study.The doses of nalbuphine were determined by up-down sequential allocation, nalbuphine 0.2 mg/kg was injected intravenously in the first child, and 5 min later medium plus long chain triglyceride propofol 2.5 mg/kg was given intravenously.Ambesh 4-point method was used to evaluate the injection pain of propofol.When the prevention of injection pain was ineffective, the dose of nalbuphine was increased in the next patient, otherwise the dose was reduced, and the difference between the two successive doses was 0.01 mg/kg.This process was repeated until the 7th turning point occurred.The ED 50 and ED 95 of nalbuphine and 95% confidence interval (CI) preventing injection pain of propofol were calculated by Probit regression. Results:The ED 50 and ED 95 (95% CI) of nalbuphine preventing medium plus long chain triglyceride propofol injection pain were 1.57 (1.50-1.62) and 1.71 (1.64-2.05) mg/kg, respectively. Conclusion:The ED 50 and ED 95 of nalbuphine preventing injection pain of medium plus long chain triglyceride propofol are 1.57 and 1.71 mg/kg, respectively, in pediatric patients undergoing gastroenteroscopy.
8.Research progression on safety verification of diving decompression procedures
ZHOU Ying jie ZHU Bao liang ZHANG Kun QING Long WANG Ye wei XU Wei gang
China Occupational Medicine 2022;49(06):712-
A diving decompression procedure is a specific rule that divers should follow when they ascend and get out of water. It
comes from the decompression theory and algorithm and is designed for the prevention of decompression sickness. With the
, ,
development of diving technology and diving medicine the decompression procedures are constantly innovated and the new
,
decompression procedure can be used in diving practice after safety verification. In principle the safety verification of
,
decompression procedures should be conducted on animal experiments before human experiments and the risks of
,
decompression sickness and oxygen toxicity should be systematically assessed. However the assessment methods used in
, , ,
different studies differ greatly thus it is urgent to establish a standard and universal verification system. Traditionally the risk
, ,
assessment of decompression sickness and oxygen toxicity is mainly carried out by observing the incidence detecting bubbles
,
theoretical calculation and lung functional test. Furthermore biochemical indicators are increasingly becoming important
, ,
supplements. Due to the special underwater environment the diving operation is prone to accidents. Therefore in addition to
,
verifying the safety of the new decompression procedure exploring its safety decompression limit is of great significance for the
formulation of emergency decompression procedures in emergency situations. The specific approach is to shorten the
decompression time and assess the safety until the critical time for detecting bubbles without the occurrence of decompression
, ,
sickness is found. Future studies should continue to optimize safety assessment methods explore sensitive biochemical markers
,
clarify species associations and improve verification efficiency and reliability of results.
9.Preparation and Pegylation of TNF-? Derivative
Yan-Wei BI ; Na LUO ; Hai-Ting LONG ; Zeng-Fu YANG ; Xu YANG ; Jian-Feng LI ; Wei-Ming XU ;
China Biotechnology 2006;0(12):-
The gene of mutated TNF-?D4 gene was amplified by overlap PCR and cloned into the prokaryotic expressive vector pBV220.TNF-?D4 contains two changes:substitutions of Pro8Arg,Ser9Lys,Asp10Arg,Ile157Phe,Leu29Ser,Arg31Val and a deletion of the N terminal four amino acids.The recombinant vector pBV220-TNF-?D4 was transformated into E.coli strain DH5?,and the high expression strain was obtained by screening monoclones.The level of expression was about 45% of total cell protein.After purification,the purity of fusion protein was above 90% by HPLC and relative ability was 8 ?107.TNF-?D4 was modificated by mPEG-ButyrALD。After purification,the purity of mPEG-TNF-?D4 was above 85% and relative ability was 8.6?107.The in vivo systemic toxicity of mPEG-TNF-?D4,which is indicated by LD50,is lower than that of rhTNF-?.These results strongly supported for the further study and exploitation of TNF-antitumor drug.
10.Polymorphism of CYP11A1 gene in Chinese patients with polycystic ovarian syndrome
Guihua GAO ; Yunxia CAO ; Long YI ; Zhaolian WEI ; Yuping XU ; Chi YANG
Chinese Journal of Obstetrics and Gynecology 2010;45(3):191-196
Objective To investigate the association between polymorphism of cytochrome P450 subfamily Ⅺ A polypeptide 1 (CYP11A1) gene and polycystic ovarian syndrome (PCOS) in Chinese population. Methods From May 2005 to Dec.2008,290 PCOS cases treated in the First affiliated hospital of Anhui Medical University matched with 344 reproductive women as controls were enrolled in this study. Genotypes of 7 tagging single nucleotide polymorphisms(tSNP,rs12438594,rs4077582,rs9806234,rsl6968477,rs4887139,rs1843090,rsl 1632698)covering CYP11A1 gene (r~2≥0.8) and 3 microsatellite markers (D15S1547,D16S520,D15S1546) were chosed from the phase II database of Han population in HapMap data.Genotype and frequency of allele were detected by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) and haplotype of gene polymorphism were analyzed in 290 PCOS cases and 344 controls.Results Among 7 tSNPs and 3 microsatellite markers,the frequency of rs4077582,D15S1547,D15S1546 and rsl 1632698 between two groups reached statistical difference (P =0.010,0.044,0.018 and 0.026).The allele frequency of rs4O77582,rs4887139,rsl843090,D15S1547 and Dl 6S520 showed significant difference between two groups(P=0.002,0.048,0.030,0.001 and 0.024).Among 5 haplotype of CYP11A1(ACGCA13/6/9AG,ACGTA16/6/11AA,GCACG12/8/8AA,GTACA14/4/7GG,GTGCA13/6/7AG),the frequency of GTACA14/4/7GG and ACGCA13/6/9AG were 7.8% (45/580) and 25.3% (147/580) in PCOS group and 11.9% and 19.6% in control group,which showed statistical difference (P< 0.05 ).There was no significant difference in the level of serum androgen at difference genotype from rs4077582 between two groups (P>0.05).Conclusion The polymorphism of CYP11A1 gene was associated with PCOS,however,the relationship between gene sequence covered by tSNP/microsatellite markers and hyperandrogenism of PCOS should be further investigated.